A higher expression of SP-D was negatively correlated with an overall survival rate in the patients without distant metastasis, HER2-negative and only intestinal-type adenocarcinoma (Figure 3D, p < 0.05). This evidence concerns the gene SFTPD and adenocarcinoma.